This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Oncobix Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Dae Ho Kang: Innovator in Cancer Treatment
Introduction: Dae Ho Kang is a prominent inventor based in Goyang-si, South Korea, recognized for his significant contribution to cancer research and treatment. He holds a valuable patent that showcases his innovative approach in the pharmaceutical field, particularly in developing compounds that target resistant cancer cells.
Latest Patents: Dae Ho Kang's notable patent is titled "Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same." This innovation describes a novel pyrimidine derivative compound, along with a salt variant, that effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells. These mechanisms are crucial as they represent some of the main resistance factors associated with third-generation EGFR anticancer agents. This research presents a promising avenue for treating lung cancer, showcasing the potential of his invention to improve patient outcomes.
Career Highlights: Dae Ho Kang's career is marked by his role at Oncobix Co., Ltd., where he continues to push the boundaries of cancer treatment. His dedication to research and development has positioned him as a key player in the pharmaceutical industry, particularly in addressing challenges posed by resistant cancer forms.
Collaborations: In his pursuit of innovation, Dae Ho Kang collaborates closely with talented colleagues such as Sung-Eun Kim and Sunho Lee. Together, they combine their expertise to advance research efforts and bring forth new therapeutic solutions that could change the landscape of cancer treatment.
Conclusion: Dae Ho Kang stands out as a remarkable inventor whose work in the field of pharmaceuticals is paving the way for enhanced treatment options for lung cancer. His innovative pyrimidine derivative compound holds the promise of tackling resistance mechanisms in cancer therapy, and through his collaborations at Oncobix Co., Ltd., he continues to contribute significantly to medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile